A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®).

Mauro M, Radich J, Douer D

Open source

DOI
10.1080/14796694.2026.2613140
Published
2026 Feb
Container
Future oncology (London, England)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2613140,
  title = {A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®).},
  author = {Mauro M and Radich J and Douer D},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2613140},
  url = {https://doi.org/10.1080/14796694.2026.2613140}
}

RIS

TY  - JOUR
TI  - A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®).
AU  - Mauro M
AU  - Radich J
AU  - Douer D
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2613140
UR  - https://doi.org/10.1080/14796694.2026.2613140
ER  - 

APA

M, M., J, R., & D, D. (2026). A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®).. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2613140

Source records